Calcitonin gene-related peptide and pain: a systematic review

1The mechanism of nociception is complex involving the detection of a noxious event by nociceptors, and signal processing in the peripheral and central nervous system (CNS). Recent studies have identified specific substances and receptors with potential roles in nociception that provide therapeutic targets, including substance P, CGRP, glutamate, serotonin, TrkA receptor, vanilloid receptor and NMDA receptor. Chronic pain resulting from disease or injury is a major public health problem and a common complaint in general population with a lifetime prevalence ranging from 12 to 30% and an enormous impact and burden on society and individuals. Despite tremendous scientific effort over the past years, current pain management treatment remains suboptimal. There is an unmet and urgent need for new effective therapeutic options for the management of chronic pain. Migraine manifests as pain with associated sensory disturbances and is considered as a chronic condition with episodic manifestations. The role of CGRP in migraine pathophysiology has gained considerable interest in recent years. This led to the development of small molecule CGRP receptor antagonists for acute and preventive treatment of migraine and monoclonal antibodies against CGRP mechanisms for migraine prevention.

2CGRP is a 37-amino-acid neuropeptide identified in 1982. It belongs to a family of peptides including adrenomedullin, amylin and calcitonin with diverse biological functions in the periphery and in the central nervous system. To what extent CGRP is involved in non-headache pain conditions is not fully clarified and whether CGRP antagonism may represent a useful therapeutic approach for the treatment of chronic pain is unknown.

3The aim of this systematic review was to assess the role of CGRP in non-headache pain in humans. In addition we discussed the potential role of anti-CGRP agents in the management of chronic pain.

4We performed a systematic literature search identifying articles reporting original data on CGRP and non-headache pain. We concluded the literature search on Pubmed Embase and ClinicalTrials.gov on May 2016. We used the following search terms: CGRP and pain. In addition, we specified our search criteria in ClinicalTrials.gov to currently available monoclonal antibodies against CGRP (LY2951742, ALD-403, PF-04427429, LBR-101/TEV-48125) or its receptor (AMG334), and CGRP receptor antagonists (BIBN4096BS, MK-0974, MK-3207, MK-1602, MK-8825, BMS-694153, BMS-927711, BMS-742413, BI 44370 TA).

5Only human studies published in English language were included. Review papers editorials and other articles without original data were excluded. We also considered articles from the reference list of studies that were found to be relevant as well as literature that was known to be relevant by the authors.

6The authors (WSS) examined the abstracts found in the literature search. Whenever the title or abstract suggested that relevant data could be part of the publication the entire article was read and discussed with the other co-authors. Studies in which patients had unclear pain history or articles without relevant data on CGRP were not included in the review.

7Our Pubmed Embase and ClinicalTrials search strategy identified 375 hits of which 50 studies were included in the final review (Fig. 1). After excluding 110 as duplicates, another 118 hits were excluded because these were abstracts, reviews, animal, migraine, headache studies, and incomplete studies. Subsequently, we excluded 97 studies that did not describe pain history of the patients, had no relevant data on CGRP, or had unclear methodology. In total, 50 studies were included in the final review (Fig. 1). The identified studies were further divided into five categories: 1) somatic pain, 2) visceral pain, 3) inflammatory pain, 4) neuropathic pain, and 5) clinical trials (Fig. 2).

8We found a total of 20 studies on the role of CGRP in somatic pain (Table 1). Using different methodological approaches and CGRP sample sources 13 studies showed higher levels of CGRP compared to controls. Eight studies directly tested for a possible correlation between pain intensity and CGRP levels. In chronic knee pain due to osteoarthrosis elevated CGRP levels were detected in serum and synovial fluid in patients compared with controls. Serum CGRP levels were positively correlated with pain intensity. Chronic low back patients due to osteoarthrosis showed decreased blood CGRP levels four months after successful auricular point acupressure pain treatment compared to baseline. No decrease was found in patients who received sham treatment. In addition, studies using immunofluorescence of skin biopsies reported decreased CGRP after acupuncture treatment of osteoarthrosis patients. Immunohistochemistry analysis of synovial tissue from fossa acetabuli showed increased CGRP levels in patients compared to controls. One study reported higher levels of CGRP in hip synovium from osteoarthritis patients compared with femoral neck patients. Moreover, one study revealed higher levels of CGRP in synovial tissue from temporomandibular joint (TMJ) pain patients compared with controls. This study also reported positive correlation between pain and CGRP levels. Biopsies from knee joint ligaments showed no difference in CGRP nerve density between patients and non-arthrosis patients. In patients with osteoarthrosis CGRP concentration in cerebrospinal fluid was decreased compared to controls.

9In patients suffering from chronic pain due to degenerative disc disease disc biopsies showed increased CGRP compared to post-mortem control discs. Biopsies from intervertebral discs in patients with low back pain contained CGRP-IR nerve fibers.

10Patients suffering from shoulder and neck pain due to whiplash injury were found to have higher blood CGRP levels compared to controls. Another study of patients with disc herniation pain reported increased blood levels of CGRP which were normalized after discectomy. Blood CGRP levels were also elevated in patients with soft tissue injury (i.e. muscle or ligament pain) compared with controls. Furthermore, one radioimmunoassay study of knee synovial fluid from patients with meniscal or ligament injury revealed higher CGRP levels compared to controls.

11Immunohistochemistry analysis of biopsies of Achilles tendons from patients with chronic painful tendinosis showed no changes in CGRP levels in patients compared to controls while another study in patients with patellar tendinosis found the presence of CGRP, but had no control group. One study reported decreased CGRP in the extensor carpi radialis brevis tendon biopsy from patients with tennis elbow compared to patients with osteochondritis.

12Samuelsson and colleagues compared CGRP levels in cerebrospinal fluid from cancer patients with pain and found no difference between patients and non-pain control patients. A microdialysis study in the vastus lateralis of the quadriceps muscles before and during pain after eccentric exercise (repetitive muscle contractions while the muscle is lengthening under load) reported increased CGRP levels during pain compared with baseline.

13Eight studies examined CGRP in different types of visceral pain conditions (Table 2).

14Immunofluorescence-based analysis of peritoneal fluid obtained during diagnostic laparoscopy in patients with endometriosis showed increased CGRP levels compared to peritoneal fluid from controls without endometriosis. Visual analogue scale scores were registered in all patients but authors found no correlation between CGRP levels and severity of pain. Immunohistochemistry analyses of peritoneal endometriotic lesions and normal peritoneum from non-endometriotic women showed increased CGRP in affected tissue material. Using the same technique, increased CGRP levels were found in endometrium and myometrium in women with, but not in those without endometriosis. Pain measurement data was not reported. CGRP levels were also studied in patients with vulvodynia. Analysis of vulval vestibule tissue revealed no differences in CGRP levels between patients with vulvodynia and controls.

15Gastric mucosal biopsies from patients with non-erosive reflux disease and functional dyspepsia were investigated with enzyme- and radioimmunoassay. None of the studies found differences in CGRP levels between patients and controls but a negative correlation between CGRP concentrations and pain scores was reported in the latter. CGRP has also been investigated with immunohistochemistry in patients with alcohol-based painful chronic pancreatitis and increased CGRP levels in patients were reported compared with pancreatic tissue from organ donors.

16Plasma CGRP levels were studied in patients with suspected or definite acute myocardial infarction at admission at a coronary care unit. This study revealed no difference in CGRP levels between patients with and without acute myocardial infarction and no difference between patients with pain and those without pain.

17Eight studies on CGRP and inflammatory pain conditions were identified (Table 3). ELISA of dermal microdialysate from volar forearm showed elevated blood CGRP levels in ten healthy volunteers with capsaicin-induced pain. No CGRP release was detected via dermal microdialysate after electrical stimulation in the same area. Correlation between pain intensity or threshold and CGRP concentration was not tested. In contrast another study found CGRP in the dialysate after histamine iontophoresis, but not after capsaicin application in the volar forearm. One study performed immunohistochemistry of skin biopsies after intradermal capsaicin injection and reported complete loss of CGRP visualization 72 h after injection.

18Using the ELISA and dermal microdialysis method in healthy volunteers CGRP release was reported after electrical stimulation upon phosphoramidon but not after captopril infusion in the volar forearm. Phosphoramidon and captopril, respectively, inhibit neutral endopeptidase and angiotensin-converting hormone, which are both involved in neuropeptide degradation.

19Immunohistochemical analysis of skin biopsies in patients with painful scars from burn showed increased CGRP compared with controls with burn scars without pain. Another study reported increased CGRP in hypertrophic burn scar compared to biopsies from unburned scars. Pain intensity was higher in patients with burn scars. Moreover ELISA of peripheral blood showed increased CGRP levels up to 24 h after burn injuries compared with healthy volunteers and in patients with pruritus due to atopic dermatitis. Furthermore, CGRP levels were positively correlated with the severity of pruritus. Nociceptive fibers have been shown to be involved in the sensation of pruritus.

20We identified 11 studies in this category (Table 4). Radioimmunoassay showed higher serum CGRP levels in 19 patients with complex regional pain syndrome (CRPS) compared to controls. The difference was normalized after a 9-month pain management therapy. In contrast another study found decreased serum CGRP levels in chronic CRPS patients (n = 12) compared with healthy controls. No correlation between pain and CGRP levels was found in either study. Moreover, immunofluorescence analysis of skin biopsies from amputated limbs in CRPS patients showed loss of CGRP expression in two patients compared with skin biopsies from five controls. Correlation between pain measures and CGRP levels was not tested. In post-herpetic neuralgia, increased CGRP expression in the affected skin compared with skin from a contralateral side in the same patient was reported by using immunofluorescence analyses of skin biopsies. In one study using immunofluorescence of skin biopsies no difference in CGRP expression was found between patients with chronic pain due to nerve injury after hand surgery and controls. The immunohistochemistry of peripheral nerve biopsies harvested from patients with Morton’s neuroma, which results in neuropathic pain, showed increased amount of CGRP in patients compared with controls.

21Four studies reported on CGRP radioimmunoassay: 1) gingival crevicular fluid in unilateral tooth pain patients 2) saliva from burning mouth syndrome patients, and 3) pulp biopsy in patients undergoing orthodontic intrusion. None of the studies reported alteration in CGRP expressions in painful sides when compared with the non-painful side or with controls.

22Attal et al. investigated 152 patients with peripheral neuropathic pain of whom 68 were treated with botulinum toxin A and 66 received placebo. CGRP was analyzed in skin biopsies using ELISA at week 1 and 4 in 23 patients who received botulinum toxin A and in 17 patients who received placebo. No difference between groups was found.

23We did not identify any clinical trials on CGRP antagonists and antibodies for the treatment of non-headache pain by searching PubMed and Embase. Search on ClinicalTrial.gov for current CGRP antagonists and antibodies for the treatment of non-headache pain only yielded three studies.

24The acute effect of PF-04427429 anti-CGRP monoclonal antibody, on attenuation of flare response after capsaicin challenge, used to induce experimental human pain, was studied in a double blind, randomized, placebo-controlled, third-party open, modified cross-over study in male healthy volunteers and using EMLA® cream as positive control. However, primary outcome measure of the study was mean blood perfusion induced by capsaicin challenge (results not reported on ClinicalTrials.gov) and no pain perception measures were studied.

25A phase 2 randomized, double-blind, placebo and active-controlled trial in patients with mild to moderate osteoarthritis knee pain failed to demonstrate efficacy of LY2951742, monoclonal antibody to CGRP. The study was terminated. A total of 266 patients were randomized to 1 of 6 treatment arms: LY2951742 5 mg, 50 mg, 120 mg, or 300 mg, celecoxib 200 mg, or placebo. Using a Bayesian dose–response longitudinal model, response rates to all four LY2951742 treatment arms were not different from placebo while celecoxib met criteria for a positive study.

26An ongoing study on remote ischemic conditioning in patients with ulcerative colitis a condition associated with abdominal pain and diarrhea is still in a recruiting phase. Investigators plan to study changes of serum and mucosal CGRP levels (secondary endpoints) in patients with ischemic colitis after remote ischemic conditioning, a repeated brief and non-harmful suppression of blood circulation induced by placing a blood pressure cuff around the right or left arm.

27The present review revealed the association between measured CGRP levels and somatic visceral, neuropathic and inflammatory pain. We found that in somatic pain conditions in particular, CGRP levels correlated with pain. Increased CGRP levels were reported in plasma, synovial and cerebrospinal fluid, tissue biopsies in individuals with degenerative disc disease, osteoarthritis and TMJ-pain. Furthermore, CGRP was elevated in acute pain conditions and pain after exercise.

28In total 13 out of 20 studies on somatic pain increased levels of CGRP were reported. Five studies showed no difference or had no control group. Four out of eight studies investigated CGRP in experimental models of inflammatory pain. The remaining four studies reported elevated CGRP levels in patients with pain caused by scars and pruritus. There was no consensus regarding correlation between neuropathic pain and CGRP levels. Six out of eleven studies showed no difference in CGRP levels, three studies reported a positive correlation, and two studies reported a negative correlation between neuropathic pain and CGRP levels. In visceral pain conditions a correlation between gynecological pain and high CGRP levels were found in tissue biopsies and peritoneal fluid. However, only two studies used a control group or control conditions.

29Thirty out of fifty studies (60%) included controls and suggested an association between CGRP levels and the respective pain condition. Twenty-six (52%) studies reported a positive association whereas four studies (8%) reported decreased CGRP levels. Studies reporting positive association investigated blood (10 studies), skin (5 studies), synovial tissue/fluid (5 studies), and other affected tissues (6 studies). Collectively, these studies showed a positive correlation between high CGRP levels and somatic pain conditions, especially osteoarthritis, acute muscular pain and chronic joint/muscular pain. These findings raise two important questions: what is the role of CGRP in the transmission of nociceptive signals and whether CGRP causes or modulates pain?

30CGRP is widely distributed in the peripheral and central nervous system and CGRP receptors are expressed in pain pathways. CGRP-like immunoreactivity (CGRP-LI) is found in 40–50% of dorsal root ganglia (DRG) neurons. CGRP-LI was found C-fiber (46%), delta-fiber (33%), and A-alpha/beta fiber (17%) neurons. Moreover, CGRP is usually co-localized with other neuropeptides, including substance P and neurokinins in DRG neurons. Peripheral CGRP-LI fibers terminate in lamina I, III and V of spinal cord and CGRP-containing DRG neurons innervate joints. Thus, CGRP and its receptors are widely distributed in peripheral and central pain pathways.

31In animals CGRP can be released from peripheral and central nerve endings upon noxious pain mechanical stimulation of the skin. In rats, the major part of circulating CGRP is released from perivascular nerve terminals. Acute and chronic nociception leads to altered release of CGRP from sensory nerve endings and central terminals into the dorsal horn of the spinal cord. In rats, CGRP applied spinally causes facilitation of central excitability and central sensitization. Kessler et al. demonstrated reduced mechanical allodynia in an animal model of OA following administration of an intrathecal CGRP receptor antagonist. Animal in vitro studies reported direct activation of nociceptors by CGRP. CGRP injected into mouse hind paw skin produced mechanical allodynia. In humans, however, a direct activation of nociceptive fibers is unlikely. CGRP injected intradermally or intramuscularly did not produce pain.

32CGRP is also found in free nerve endings in skin and synovium) and perivascular afferents in different structures in both humans and animals. The release of CGRP from these fibers causes vasodilation suggesting a role in neurogenic inflammation. The question is whether CGRP exerts either pro- or anti-inflammatory/nociceptive effects. It is possible that CGRP release reflects the response of the nocifensor system to injury and inflammation to evoke protective vasodilatation. Deficiency of alpha CGRP (αCGRP knockout mice) was associated with enhanced inflammatory responses in the hippocampus and hypothalamus and reduced the survival rate compared to wild-type mice in septic shock condition. However, αCGRP knockout mice displayed lower pain sensitivity to heat stimulation faster accumulation of c-Fos compared to wild-type animals after incision and complete Freund’s adjuvant injection. In animals, sustained CGRP release may induce peripheral sensitization likely due to release of inflammatory mediators (bradykinin, prostaglandins, etc.) from nerve endings and cells of immune system.

33Inflammatory diseases of the joints tendons and discs may be associated with elevated levels of CGRP (Additional files 1 and 2: Tables S1 and S2). These data suggest that abnormal release of CGRP could be a marker of sensory afferent activation. Comparing CGRP changes in different tissue materials (i.e. blood, synovium, skin, CSF, ligament tissue, mucosa, etc.), it seems that elevated CGRP is more frequently found in blood, synovium and skin. Bullock et al. suggested that CGRP release during joint degeneration in osteoarthritis might play an important role in the peripheral sensitization and proposed possible analgesic effect of CGRP antagonists in this condition. CGRP stimulates proliferation and migration of human endothelial cells, causing angiogenesis with the co-localized CGRP-containing perivascular nerve fibers. Intra-articular growth of CGRP-containing perivascular nociceptors have been reported in patients with osteoarthritis. It has further been shown that nociceptive nerve fibers innervating joints are sensitized in these patients contributing to the experience of pain. Immunohistochemistry of forearm skin biopsies in patients with congenital insensitivity to pain (CIP) showed reduced amount of CGRP compared to controls. Thus, measurement of CGRP may be regarded a marker of sensory afferent activation in the respective tissue during a pain condition. This indicates that CGRP not only contributes to proliferation of CGRP-containing nociceptors, but could sensitize these nociceptors via neurogenic inflammation in humans. Whether CGRP causes pain per se can be examined by application of exogenous CGRP. Interestingly, dose-dependent angiogenesis after intra-articular CGRP injection in the rat knee can be blocked by the CGRP receptor antagonist, BIBN4096BS. One way of exploring this hypothesis would be to study CGRP levels in humans after exposure to painful stimuli. In healthy volunteers, intradermal capsaicin injections produced a steady increase of CGRP levels in the first sampling period, but failed to reach significance in the second session. The latter could be explained by capsaicin-induced desensitization of neuropeptide release from primary afferents. Another study demonstrated that capsaicin-induced vasodilation in the human skin was mainly mediated by CGRP and not by other substances with vasodilator properties including prostaglandins, nitric oxide, or substance P. Only few studies have investigated the effect of CGRP antagonist after intradermal capsaicin injections. Chi-Chung Li et al. reported that CGRP antagonist MK-3207 inhibited capsaicin-induced vasodilation in skin. Sinclair et al. demonstrated reduced increase in dermal blood flow after topical capsaicin application in the forearm of healthy volunteers who were pretreated with CGRP antagonist (telcagepant). The degree of inhibition in capsaicin-induced dermal blood flow was shown to be increased with higher LY2951742, CGRP monoclonal antibody, plasma concentrations suggesting dose–response relationship.

34While increased CGRP levels in the affected tissue and synovial material indicate ingrowth of pain sensitive nerve fibers in the tissue it is unclear why CGRP level increases in blood and skin. CGRP is synthesized in central and peripheral neurons. Two studies investigated CGRP levels in the cerebrospinal fluid during pain and found 1) no difference in cancer pain patients compared to controls, and 2) low CGRP levels in osteoarthrosis patients. In contrast, biochemical studies in osteoarthrosis patients reported a positive association between pain and CGRP levels in blood, synovial material, and skin. Dermal electrical current stimulation in humans caused increased CGRP in blood. However, a recent study randomized, double-blind, placebo and active-controlled study in patients with osteoarthritis knee pain did not demonstrate efficacy of LY2951742, monoclonal antibody to CGRP against placebo and the trial was terminated. However, the study was only done in patients with mild and moderate symptoms. It is possible that patients with severe osteoarthritis involving other joints may respond differently. Other factors that may confound the results include the long duration of the disease (not reported in abstract), which can indicate presence of central sensitization and level of activity of patients that may worsen symptoms including pain. No studies to date have investigated the efficacy of monoclonal antibodies against CGRP receptor in patients with osteoarthritis knee pain.

35Further studies addressing these issues are warranted.

36The present review suggests that CGRP may play a role in pain transmission in somatic pain conditions such as joint and muscular chronic pain. CGRP might have a pro-inflammatory role in peripheral nervous system by leading to release of pro-nociceptive substances and by facilitating central nociceptive transmission and contributing to central sensitization. However, the exact mechanisms and involvement of CGRP in nociceptive processing are not fully clarified. Understanding these mechanisms may lead to the potential development of new pharmacotherapies targeting CGRP and its receptors. Efficacy and safety of the CGRP antagonists and antibodies has already been established in migraine and this paves the way for more clinical trials in non-headache pain conditions.